【摘要】 目的探讨CT引导下经皮穿刺氩氦冷冻消融治疗鼻咽癌肝转移瘤的安全性及疗效。方法回顾分析16例行经皮穿刺氩氦冷冻消融治疗鼻咽癌肝转移瘤患者的临床资料,观察术前术后患者生活质量及术后并发症,统计患者冷冻术后疾病无进展生存时间(PFS)、总生存期(OS)、术后1、3、6和12个月肿瘤局部控制率。结果所有患者冷冻消融治疗术后均未出现严重并发症且生活质量明显提高,术后1、3、6和12个月肿瘤局部控制率分别为100%、87.5%,80.0%,58.3%,PFS为11个月(95%CI:8.4～13.6个月),中位OS为19个月(95%CI:9.2～28.8个月),术后半年、1年及2年生存率分别为93.8%、75%及43.8%。结论 CT引导下经皮穿刺氩氦冷冻消融治疗鼻咽癌肝转移瘤疗效确切,创伤微小,安全有效。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of CT-guided percutaneous argon-helium cryoablation in treating hepatic metastases from nasopharyngeal carcinoma. Methods The clinical data of 16 patients with hepatic metastases from nasopharyngeal carcinoma, who had received percutaneous argonhelium cryoablation therapy, were retrospectively analyzed. The quality of life before and after therapy, and the postoperative complications were recorded. After argon-helium cryoablation therapy, the progression-free survival(PFS), the overall survival(OS), and the one-month, 3-month, 6-month, 12-month postoperative tumor local control rates were calculated. Results In all 16 patients, no severe complications occurred and the quality of life was significantly improved after argon-helium cryoablation therapy. The one-month, 3-month, 6-month, 12-month postoperative tumor local control rates were 100%, 87.5%, 80.0% and 58.3%respectively. The median PFS was 11 months(95%CI: 8.4-13.6 months), and the median survival time was19 months(95%CI: 9.2-28.8 months). After argon-helium cryoablation therapy, the half-year, one-year and2-year survival rates were 93.8%, 75% and 43.8% respectively. Conclusion For the treatment of hepatic metastases from nasopharyngeal carcinoma,CT-guided percutaneous argon-helium cryoablation is minimally-invasive, safe and effective with reliable curative effect.更多还原